Clinical trials: Active Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE)
Clinical Study of Cizutamig in Systemic Lupus Erythematosus
The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of Cizutamig in patients with Systemic Lupus Erythematosus
- Trial name
- NCT07215663
- Testing
- Cizutamig
- Where
- 17 sites in China
- Volunteers
- 47 people
- Sponsor
- Candid Therapeutics
Lupus Arthritis, Systemic Lupus Erythematosus
Safety Study of AMG 557 in Subjects With Lupus Arthritis
This is a multicenter, randomized, double-blind, parallel, placebo-controlled, multiple dose study that will enroll approximately 40 systemic lupus erythematosus subjects with active lupus arthritis.
- Trial name
- NCT01683695
- Testing
- AMG 557
- Where
- 13 sites in United States, Australia and 6 more
- Volunteers
- 20 people
- Sponsor
- Amgen
Systemic Lupus Erythematosus
The Systemic Lupus Erythematosus (SLE) Activity Gene Expression (SAGE) Study
The goal of this study is to enable the study sponsor to develop a new blood test method for clinicians to accurately predict which individuals with lupus will flare, when the flare will occur, and flare severity.
- Trial name
- SAGE (NCT00671047)
- Testing
- non-interventional
- Where
- 12 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- XDx
Active Systemic Lupus Erythematosus
Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in Asian participants with active systemic lupus erythematosus (SLE).
- Trial name
- NCT04931563
- Testing
- Anifrolumab
- Where
- 65 sites in China, Hong Kong and 4 more
- Volunteers
- 277 people
- Sponsor
- AstraZeneca
Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic
Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions
The purpose of this study is to determine the safety, efficacy and tolerability of topical R333 ointment in Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) patients with active discoid lesions.
- Trial name
- SKINDLE (NCT01597050)
- Testing
- R932333
- Where
- 15 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Rigel Pharmaceuticals
Lupus Erythematosus, Systemic
Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.
The primary objective of the study is to evaluate the safety, tolerability, and efficacy of 4 weeks intravenous treatment with Cpn10 in subjects with mild to moderate active SLE.
- Trial name
- NCT01838694
- Testing
- Ala-Cpn10
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Invion, Inc.
Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN)
A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)
This Phase 1, open label, dose escalation study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of HB2198, a tetravalent bispecific anti CD19/CD20 antibody, in adults with…
- Conditions
- Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN), Extra-renal Lupus (ERL)
- Trial name
- NCT07491900
- Testing
- HB2198
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Hinge Bio
Systemic Lupus Erythematosus
Exploratory Study of Changes in Disease Activity and Biomarkers With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE)
This is an exploratory open label single arm study to evaluate changes in disease activity and biomarkers in patients with mild active SLE, during treatment with ABR-215757 given as add-on to standard therapy.
- Trial name
- NCT00997100
- Testing
- paquinimod (ABR-215757)
- Where
- 4 sites in Denmark, Sweden
- Volunteers
- 13 people
- Sponsor
- Active Biotech AB
Lupus Erythematosus, Systemic
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cevostamab in participants with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN).
- Trial name
- NCT07629583
- Testing
- Cevostamab, Tocilizumab
- Where
- 11 sites in Australia, Brazil and 4 more
- Volunteers
- 46 people
- Sponsor
- Genentech, Inc.